Literature DB >> 7837819

Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels.

S Pakkala1, S de Vos, E Elstner, R K Rude, M Uskokovic, L Binderup, H P Koeffler.   

Abstract

In vitro, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) induces differentiation of HL-60 cells and inhibits their proliferation as well as the proliferation of leukemic cells from patients. In vivo, the survival of mice challenged with syngeneic leukemic cells is enhanced by treatment with 1,25(OH)2D3. Patients treated with 1,25(OH)2D3 develop hypercalcemia at a serum level of 2 x 10(-10) mol/l which is a concentration too low to achieve an antileukemic effect in vitro. Several interesting vitamin D3 analogs have recently been developed. We initially examined the effect of 1,25(OH)2-16ene-23yne-19-nor-26,27-F6-D3 and 24a,26a,27a-tri-homo-22,24-diene-1-alpha,25-(OH)2-D3 on clonal growth and differentiation of HL-60 cells. Each of the analogs had comparable effects on clonal growth with 50% inhibition (ED50) at concentrations of 0.2-0.5 x 10(-9) M; 1,25(OH)2D3 was about 20- to 50-fold less active in inhibiting growth. Differentiation was determined by induction of superoxide production, as measured by nitroblue tetrazolium (NBT) reduction and by expression of a macrophage-specific enzyme (alpha napthyl acetate esterase (ANAE)). The 24a,26a,27a-tri-homo-22,24-diene-1-alpha,25-(OH)2-D3 and 1,25(OH)2-16ene-23yne-19-nor-26,27-F6-D3 were about 5- to 14-fold more potent than 1,25(OH)2D3. The hypercalcemia inducing side-effects of these analogs and three other previously identified, extremely potent vitamin D3 compounds, as well as 1,25(OH)2D3, were studied. The analogs were administered intraperitoneally every other day (qod) for 5 weeks; serum was collected weekly and Ca2+ measured by atomic absorption spectrophotometry. The highest tolerated dose of each analog leaving all mice alive was for 1,25(OH)2D3: 0.25 micrograms; 1,25(OH)2-24a,26a,27a-tri-homo-22,24-diene-D3: 0.25 micrograms; and 1,25(OH)2-16ene-23yne-19-nor-26,27-F6-D3: 0.0625 micrograms. Another hexafluoro compound with potent abilities to induce differentiation (1,25(OH)2-16ene-23yne-26,27-F6-D3) was very toxic, all mice died in the second week while receiving 0.0625 micrograms qod. Prior studies showed that the most potent compound in inducing differentiation of HL-60 was 1,25(OH)2-20-epi-D3; but it is very toxic as only one mouse survived a dose of > or = 0.0125 micrograms qod for 5 weeks. 1,25(OH)2-16ene-23yne-D3 is an extremely active inducer of differentiation but, on the other hand, it has low potential to produce hypercalcemia; mice maintained normal serum calcium levels even while receiving 2 micrograms qod for 5 weeks.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7837819     DOI: 10.1016/0145-2126(94)00065-i

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  11 in total

Review 1.  Differentiation therapy of leukemia: 3 decades of development.

Authors:  Daniel Nowak; Daphne Stewart; H Phillip Koeffler
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

2.  Apc(MIN) modulation of vitamin D secosteroid growth control.

Authors:  Haibo Xu; Gary H Posner; Michael Stevenson; Frederick C Campbell
Journal:  Carcinogenesis       Date:  2010-05-20       Impact factor: 4.944

3.  Vitamin D3 analogs inhibit growth and induce differentiation in LA-N-5 human neuroblastoma cells.

Authors:  T B Moore; H P Koeffler; J M Yamashiro; R K Wada
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

4.  Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25-dihydroxyvitamin D₃.

Authors:  Jing Zhang; Jonathan S Harrison; George P Studzinski
Journal:  Exp Cell Res       Date:  2010-09-08       Impact factor: 3.905

5.  Effects of vitamin D on the growth of normal and malignant B-cell progenitors.

Authors:  R Consolini; S Pala; A Legitimo; G Crimaldi; S Ferrari; S Ferrari
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

Review 6.  Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy.

Authors:  Philip J Hughes; Ewa Marcinkowska; Elzbieta Gocek; George P Studzinski; Geoffrey Brown
Journal:  Leuk Res       Date:  2009-10-06       Impact factor: 3.156

7.  Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1alpha-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea.

Authors:  M Makishima; J Okabe-Kado; Y Honma
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

8.  Synergistic inhibition of prostate cancer cell lines by a 19-nor hexafluoride vitamin D3 analogue and anti-activator protein 1 retinoid.

Authors:  M J Campbell; S Park; M R Uskokovic; M I Dawson; L Jong; H P Koeffler
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

9.  Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation.

Authors:  Noriyoshi Iriyama; Bo Yuan; Yoshihiro Hatta; Norio Takagi; Masami Takei
Journal:  Cancer Cell Int       Date:  2016-05-13       Impact factor: 5.722

10.  Vitamin D3: A Role in Dopamine Circuit Regulation, Diet-Induced Obesity, and Drug Consumption.

Authors:  Joseph R Trinko; Benjamin B Land; Wojciech B Solecki; Robert J Wickham; Luis A Tellez; Jaime Maldonado-Aviles; Ivan E de Araujo; Nii A Addy; Ralph J DiLeone
Journal:  eNeuro       Date:  2016-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.